SecBot SecBot
PRESS-RELEASE ·Filed Apr 15, 2026

NKTX

Nkarta, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Outpatient dosing and redosing flexibility meaningfully de-risk the clinical program and improve feasibility of future commercialization. Traders should monitor upcoming data presentations for efficacy signals, which could serve as a near-term catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.80
T+0 close · Apr 15, 2026 · via day close
Latest settled
−0.36%
T+60 · $2.79
Vs SPY
−7.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $2.80entry
  2. T+1 · 7mo ago +23.93%α +22.71% · $3.47
  3. T+5 · 7mo ago +6.43%α +5.44% · $2.98
  4. T+20 · 6mo ago +9.29%α +3.47% · $3.06
  5. T+60 · 4mo ago −0.36%α −7.40% · $2.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing, redosing flexibility, and expansion into rheumatoid arthritis. These changes reduce patient burden and broaden trial accessibility, supporting clinical development of its CAR-NK therapy NKX019 for autoimmune diseases.

Key Facts

  • FDA agreed to protocol amendments allowing outpatient administration of NKX019 with monitoring reduced from 24 hours to 2 hours
  • Option to re-dose patients added in both Ntrust-1 and Ntrust-2 trials
  • Rheumatoid arthritis cohort to be added to Ntrust-2 trial
  • No geographic monitoring requirements remain, reducing patient burden
  • Initial data from trials expected to be presented at a medical meeting in 2026

Financial Impact

Non-dilutive clinical advancement with potential to accelerate development timeline and expand market reach

clinical progressdevelopment timelinepatient recruitmentregulatory pathway

Risk Factors

  • Clinical trial results may not be predictive of future outcomes
  • Potential delays in enrollment or IRB approvals for amended protocols

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274856

Track record

13 reports on NKTX

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Viewing Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026